Semus Wealth Partners LLC Increases Stake in Eli Lilly and Company (NYSE:LLY)

Semus Wealth Partners LLC boosted its stake in Eli Lilly and Company (NYSE:LLY) by 27.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,101 shares of the company’s stock after purchasing an additional 664 shares during the period. Eli Lilly and Company comprises 1.9% of Semus Wealth Partners LLC’s investment portfolio, making the stock its 13th largest position. Semus Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $2,747,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the business. MidAtlantic Capital Management Inc. purchased a new position in shares of Eli Lilly and Company during the third quarter valued at approximately $30,000. Napa Wealth Management increased its stake in shares of Eli Lilly and Company by 379.2% during the third quarter. Napa Wealth Management now owns 3,048 shares of the company’s stock valued at $2,700,000 after buying an additional 2,412 shares during the period. Cassaday & Co Wealth Management LLC increased its stake in shares of Eli Lilly and Company by 2.1% during the third quarter. Cassaday & Co Wealth Management LLC now owns 5,570 shares of the company’s stock valued at $4,935,000 after buying an additional 113 shares during the period. Drive Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 3.0% during the third quarter. Drive Wealth Management LLC now owns 2,310 shares of the company’s stock valued at $2,046,000 after purchasing an additional 68 shares in the last quarter. Finally, Strengthening Families & Communities LLC boosted its holdings in Eli Lilly and Company by 726.0% in the third quarter. Strengthening Families & Communities LLC now owns 3,659 shares of the company’s stock worth $3,242,000 after acquiring an additional 3,216 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $739.39 on Monday. The business has a 50-day moving average price of $882.65 and a 200-day moving average price of $871.04. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53. The firm has a market cap of $701.92 billion, a price-to-earnings ratio of 80.67, a price-to-earnings-growth ratio of 2.82 and a beta of 0.43. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the previous year, the company posted $0.10 earnings per share. Eli Lilly and Company’s quarterly revenue was up 20.4% on a year-over-year basis. As a group, equities research analysts predict that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.70%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Truist Financial upped their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. JPMorgan Chase & Co. upped their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Guggenheim upped their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Finally, Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective for the company. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,007.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.